ArticleBMC public health2025
Assessment of SARS-CoV-2 neutralizing antibody persistence using LFIC: a prevalence study after booster doses.
Article in BMC public health, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe primary immunization against SARS-CoV-2 has yielded protection rates of up to 95%. The evolution of the original strain of SARS-CoV-2 towards emerging variants which have higher transmissibility, severity of disease and greater viral escape, have promoted the necessity of vaccine booster doses. The third dose of the vaccine provides protection, but its long-term durability remains uncertain. Our aim was to know the vaccine coverage at the University of Alicante (UA) after one year of administration of vaccine booster doses through the detection of anti-SARS-CoV-2 antibodies with a rapid serological test.
methodsA cross-sectional study was carried out on the prevalence of antibodies against Spike protein of SARS-CoV-2 using a serological test based on lateral flow immunochromatography. We applied a logistic regression to the available variables by the statistics program SPSS 29.0.
results565 subjects were tested, 70.1% were women and the average age was 48.2 years old. 93.5% of the tests performed indicated the presence of Spike-protein antibodies against SARS-CoV-2. The time since the last exposure to the viral antigens, whether via vaccination or via infection, revealed an increase in the odds of returning a negative result for antibodies against SARS-CoV-2.
conclusionsOur results reinforce the temporary nature of the protection of anti-SARS-CoV-2 antibodies and the need for booster doses, supporting the continuity of vaccinations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.